Checks and balances: Interplay of RTKs and PTPs in cancer progression

Sarita K. Sastry, Lisa Elferink

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

In recent years, targeted therapies for receptor tyrosine kinases (RTKs) have shown initial promise in the clinical setting for the treatment of several tumors driven by these oncogenic signaling pathways. Unfortunately, clinical relapse due to acquired resistance to these molecular therapeutics is common. An improved understanding of how tumors bypass the inhibitory effects of RTK-targeted therapies has revealed a rich myriad of possible mechanisms for acquired resistance. Protein tyrosine phosphatases (PTPs) can function as oncogenes or tumor suppressors to either enhance or suppress RTK signaling. Recent studies suggest that the loss or gain of function of PTP's can significantly impinge on RTK signaling during tumor progression. Here we review the interplay between RTKs and PTPs as an emerging mechanism for acquired resistance to RTK-targeted therapies, that may aid in the design of improved therapies to prevent and overcome resistance in treatments for cancer patients.

Original languageEnglish
Pages (from-to)435-440
Number of pages6
JournalBiochemical Pharmacology
Volume82
Issue number5
DOIs
StatePublished - Sep 1 2011

Fingerprint

Protein Tyrosine Phosphatases
Receptor Protein-Tyrosine Kinases
Tumors
Neoplasms
Therapeutics
Oncogenes
Recurrence

Keywords

  • Acquired resistance
  • Cancer
  • Phosphatase
  • Receptor tyrosine kinase

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry

Cite this

Checks and balances : Interplay of RTKs and PTPs in cancer progression. / Sastry, Sarita K.; Elferink, Lisa.

In: Biochemical Pharmacology, Vol. 82, No. 5, 01.09.2011, p. 435-440.

Research output: Contribution to journalArticle

@article{7d98861838774f199b167a25743c42cb,
title = "Checks and balances: Interplay of RTKs and PTPs in cancer progression",
abstract = "In recent years, targeted therapies for receptor tyrosine kinases (RTKs) have shown initial promise in the clinical setting for the treatment of several tumors driven by these oncogenic signaling pathways. Unfortunately, clinical relapse due to acquired resistance to these molecular therapeutics is common. An improved understanding of how tumors bypass the inhibitory effects of RTK-targeted therapies has revealed a rich myriad of possible mechanisms for acquired resistance. Protein tyrosine phosphatases (PTPs) can function as oncogenes or tumor suppressors to either enhance or suppress RTK signaling. Recent studies suggest that the loss or gain of function of PTP's can significantly impinge on RTK signaling during tumor progression. Here we review the interplay between RTKs and PTPs as an emerging mechanism for acquired resistance to RTK-targeted therapies, that may aid in the design of improved therapies to prevent and overcome resistance in treatments for cancer patients.",
keywords = "Acquired resistance, Cancer, Phosphatase, Receptor tyrosine kinase",
author = "Sastry, {Sarita K.} and Lisa Elferink",
year = "2011",
month = "9",
day = "1",
doi = "10.1016/j.bcp.2011.06.016",
language = "English",
volume = "82",
pages = "435--440",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Checks and balances

T2 - Interplay of RTKs and PTPs in cancer progression

AU - Sastry, Sarita K.

AU - Elferink, Lisa

PY - 2011/9/1

Y1 - 2011/9/1

N2 - In recent years, targeted therapies for receptor tyrosine kinases (RTKs) have shown initial promise in the clinical setting for the treatment of several tumors driven by these oncogenic signaling pathways. Unfortunately, clinical relapse due to acquired resistance to these molecular therapeutics is common. An improved understanding of how tumors bypass the inhibitory effects of RTK-targeted therapies has revealed a rich myriad of possible mechanisms for acquired resistance. Protein tyrosine phosphatases (PTPs) can function as oncogenes or tumor suppressors to either enhance or suppress RTK signaling. Recent studies suggest that the loss or gain of function of PTP's can significantly impinge on RTK signaling during tumor progression. Here we review the interplay between RTKs and PTPs as an emerging mechanism for acquired resistance to RTK-targeted therapies, that may aid in the design of improved therapies to prevent and overcome resistance in treatments for cancer patients.

AB - In recent years, targeted therapies for receptor tyrosine kinases (RTKs) have shown initial promise in the clinical setting for the treatment of several tumors driven by these oncogenic signaling pathways. Unfortunately, clinical relapse due to acquired resistance to these molecular therapeutics is common. An improved understanding of how tumors bypass the inhibitory effects of RTK-targeted therapies has revealed a rich myriad of possible mechanisms for acquired resistance. Protein tyrosine phosphatases (PTPs) can function as oncogenes or tumor suppressors to either enhance or suppress RTK signaling. Recent studies suggest that the loss or gain of function of PTP's can significantly impinge on RTK signaling during tumor progression. Here we review the interplay between RTKs and PTPs as an emerging mechanism for acquired resistance to RTK-targeted therapies, that may aid in the design of improved therapies to prevent and overcome resistance in treatments for cancer patients.

KW - Acquired resistance

KW - Cancer

KW - Phosphatase

KW - Receptor tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=79960925570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960925570&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2011.06.016

DO - 10.1016/j.bcp.2011.06.016

M3 - Article

C2 - 21704606

AN - SCOPUS:79960925570

VL - 82

SP - 435

EP - 440

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 5

ER -